ArticleMedicine2026
Efficacy and safety of Wuwei Xiaodu Drink in root canal therapy for chronic pulpitis: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pulpitis often leads to post-root canal therapy (RCT) complications. Wuwei Xiaodu Drink (WWXDD), a traditional anti-inflammatory formula, may enhance RCT efficacy. The objective was to assess WWXDD combined with RCT for chronic pulpitis, focusing on pain, inflammation, tissue repair, and safety. A retrospective study of 600 patients (300 RCT only vs 300 RCT + 14-day WWXDD) was conducted. Outcomes included pain (Visual Analog Scale), inflammatory markers (C-reactive protein, tumor necrosis factor-alpha, interleukin-6, interleukin-8), growth factors (basic fibroblast growth factor, vascular endothelial growth factor, bone morphogenetic protein-2), periodontal indices (Gingival Index, Plaque Index, Periodontal Probing Depth), and adverse events. WWXDD group showed lower Visual Analog Scale scores (days 7/14/28, P < .001), reduced inflammation (C-reactive protein: 7.13 vs 8.54 mg/L; tumor necrosis factor-alpha: 48.57 vs 57.28 ng/L), improved periodontal indices (Gingival Index: 0.71 vs 0.84; Periodontal Probing Depth: 1.43 vs 1.68 mm, P < .001), and higher growth factors (basic fibroblast growth factor: 43.75 vs 41.22 pg/μL). Adverse events were lower (6.00% vs 11.00%, P = .028), with superior efficacy (94.33% vs 89.33%, P = .025). WWXDD synergizes with RCT to alleviate pain, suppress inflammation, enhance repair, and improve safety. Integrating traditional medicine optimizes chronic pulpitis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.